<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02768597</url>
  </required_header>
  <id_info>
    <org_study_id>15-006839</org_study_id>
    <nct_id>NCT02768597</nct_id>
  </id_info>
  <brief_title>Comparing The Outcome of Large-Diameter vs Small-Diameter Glenospheres in Primary Reverse Shoulder Arthroplasty</brief_title>
  <official_title>A Prospective, Randomized Study Comparing The Outcome of Large-Diameter vs Small-Diameter Glenospheres in Primary Reverse Shoulder Arthroplasty Using the ReUnion System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stryker Nordic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare the outcome of primary reverse shoulder arthroplasty using the Stryker
      ReUnion System with implantation of either a large (40 mm) or a small (36 mm) glenosphere
      with either a +2 mm or a +6 mm offset.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 220 shoulders will be included in the study (55 shoulders in each of the four
      groups). Each shoulder will be assessed preoperatively, at 3 weeks, 3 months, one year, two
      years and five years. The primary end-point will be range of motion at one year. Additional
      end-points will include dislocation, stress fractures of the acromion, metal ion levels in
      peripheral blood, neurovascular complications, radiographic notching, implant mechanical
      failure and revision surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Shoulder range of motion</measure>
    <time_frame>One year</time_frame>
    <description>The primary outcome will be shoulder range of motion in elevation, external rotation, and internal rotation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxford Shoulder Score questionnaire</measure>
    <time_frame>One year</time_frame>
    <description>The analysis will focus on comparing the subjects randomized to the small glenosphere to the patients randomized to the large glenosphere.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American Shoulder and Elbow Surgeons (ASES) scale</measure>
    <time_frame>One year</time_frame>
    <description>The analysis will focus on comparing the subjects randomized to the small glenosphere to the patients randomized to the large glenosphere.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick-DASH questionnaire</measure>
    <time_frame>One year</time_frame>
    <description>The analysis will focus on comparing the subjects randomized to the small glenosphere to the patients randomized to the large glenosphere.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Glenohumeral Joint Degeneration</condition>
  <arm_group>
    <arm_group_label>Large-Diameter Glenosphere +2 mm offset</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +2 mm offset</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Small-Diameter Glenosphere +2 mm offset</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +2 mm offset</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Large-Diameter Glenosphere +6 mm offset</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +6 mm offset</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Small-Diameter Glenosphere +6 mm offset</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +6 mm offset</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ReUnion System with a Large-Diameter Glenosphere +2 mm offset</intervention_name>
    <description>Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +2 mm offset</description>
    <arm_group_label>Large-Diameter Glenosphere +2 mm offset</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ReUnion System with a Small-Diameter Glenosphere +2 mm offset</intervention_name>
    <description>Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +2 mm offset</description>
    <arm_group_label>Small-Diameter Glenosphere +2 mm offset</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ReUnion System with a Large-Diameter Glenosphere +6 mm offset</intervention_name>
    <description>Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +6 mm offset</description>
    <arm_group_label>Large-Diameter Glenosphere +6 mm offset</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ReUnion System with a Small-Diameter Glenosphere +6 mm offset</intervention_name>
    <description>Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +6 mm offset</description>
    <arm_group_label>Small-Diameter Glenosphere +6 mm offset</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects willing to sign the informed consent

          -  Male and non-pregnant female subjects ages 50 - 90 at the time of surgery

          -  Subjects requiring a primary reverse total shoulder arthroplasty

          -  Subjects with the diagnosis of cuff-tear arthropathy (CTA), massive irreparable
             rotator cuff tear (MRCT) or osteoarthritis (OA) with marked posterior subluxation or
             bone loss

        Exclusion Criteria:

          -  Inability to comply with follow-up requirements

          -  Subjects with inflammatory arthritis

          -  Subjects with proximal humerus fractures

          -  Subjects with sequels of trauma

          -  Subjects that are immunologically compromised

          -  Subjects with an active or suspected latent infection in or about the shoulder

          -  Need to add a tendon transfer

          -  Need for structural humeral bone graft

          -  Pregnant subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Morrey, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teron Cox</last_name>
    <phone>(507) 538-3560</phone>
    <email>cox.teron@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2016</study_first_posted>
  <last_update_submitted>August 18, 2017</last_update_submitted>
  <last_update_submitted_qc>August 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Mark E. Morrey, M.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

